3 stories found
FDA chief Marty Makary addresses the contentious period for the agency, marked by significant staff and budget cuts, and discusses changes to vaccine policy and the use of compounded GLP-1s.
The FDA chief warns that the U.S. is falling behind China in early drug development and calls for faster trial approvals to address bottlenecks in hospital contracting, ethical reviews, and Investigational New Drug applications.
The U.S. Food and Drug Administration has reversed its earlier decision and will now review Moderna's application for its modified influenza vaccine.